Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SIV infection duration largely determines broadening of neutralizing antibody response in macaques
Fan Wu, Ilnour Ourmanov, Andrea Kirmaier, Sivan Leviyang, Celia LaBranche, Jinghe Huang, Sonya Whitted, Kenta Matsuda, David Montefiori, Vanessa M. Hirsch
Fan Wu, Ilnour Ourmanov, Andrea Kirmaier, Sivan Leviyang, Celia LaBranche, Jinghe Huang, Sonya Whitted, Kenta Matsuda, David Montefiori, Vanessa M. Hirsch
View: Text | PDF
Research Article AIDS/HIV Virology

SIV infection duration largely determines broadening of neutralizing antibody response in macaques

  • Text
  • PDF
Abstract

The development of broadly neutralizing antibodies (BNAbs) in HIV infection is a result of long-term coevolutionary interaction between viruses and antibodies. Understanding how this interaction promotes the increase of neutralization breadth during infection will improve the way in which AIDS vaccine strategies are designed. In this paper, we used SIV-infected rhesus macaques as a model to study the development of neutralization breadth by infecting rhesus macaques with longitudinal NAb escape variants and evaluating the kinetics of NAb response and viral evolution. We found that the infected macaques developed a stepwise NAb response against escape variants and increased neutralization breadth during the course of infection. Furthermore, the increase of neutralization breadth correlated with the duration of infection but was independent of properties of the inoculum, viral loads, or viral diversity during infection. These results imply that the duration of infection was the main factor driving the development of BNAbs. These data suggest the importance of novel immunization strategies to induce effective NAb response against HIV infection by mimicking long-term infection.

Authors

Fan Wu, Ilnour Ourmanov, Andrea Kirmaier, Sivan Leviyang, Celia LaBranche, Jinghe Huang, Sonya Whitted, Kenta Matsuda, David Montefiori, Vanessa M. Hirsch

×

Figure 4

Statistical analysis of factors associated with the increase of neutralization breadth during infection.

Options: View larger image (or click on image) Download as PowerPoint
Statistical analysis of factors associated with the increase of neutrali...
(A–C) Macaques divided into 3 groups based on the inoculated viruses and the kinetics of NAb titers against SIVsmE660-FL14 tier 1 (A), H807-16w-6 tier 2 (B), and H807-24w-4 tier 3 (C) are shown as the geometric mean with 95% CI (n = 6 for each group). The different inoculated viruses did not make a significant difference on NAb titers against tier 1 (P = 0.3353, A), tier 2 (P = 0.9261, B), or tier 3 (P = 0.7609, C) viruses, whereas infection time made a significant difference on NAb titers against all 3 viruses (P < 0.001, repeated-measures 2-way ANOVA). To analyze the effect of viral loads on NAb titers, macaques were divided into suppressors or nonsuppressors based on the plasma viremia at the chronic phase of infection. Macaques Rh844, Rh845, Rh847, Rh852, Rh853, and Rh854, whose plasma viremia was below 104 copies, were designated as suppressors (n = 6), and the other macaques, whose plasma viremia was above 104 copies, were designated as nonsuppressors (n = 12). (D–F) The kinetics of NAb titers against SIVsmE660-FL14 tier 1 (D), H807-16w-6 tier 2 (E), and H807-24w-4 tier 3 (F) in suppressors and nonsuppressors are shown as geometric mean with 95% CI. The different plasma viremia did not make a significant difference on NAb titers against tier 1 (P = 0.0762, D), tier 2 (P = 0.2614, E), or tier 3 (P = 0.9592, F) viruses, whereas infection time made a significant difference on NAb titers against all 3 viruses (P < 0.01, repeated-measures 2-way ANOVA).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts